Study S000102

The Effect of Probiotics on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Therapy in Patients With Obesity: A Randomized, Double-Blind, Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07847593
Acronym: ProSem
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 102
Start: 2025-07-09
Primary completion: 2026-07-15
Lead sponsor: Nordic Biotic Sp. z o.o.
Conditions: Obesity (Disorder); GLP-1 Receptor Agonist Treatment; Probiotic Intervention; Diabetes Mellitus Type 2
Interventions: DIETARY_SUPPLEMENT:Four-strain probiotic formulation; DIETARY_SUPPLEMENT:Maltodextrin (Placebo)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Gastrointestinal adverse event incidence proportion during semaglutide treatment [During the 12-week semaglutide treatment and dose-escalation period]
Prevalence of gastrointestinal adverse events during semaglutide treatment [During the 12-week semaglutide treatment and dose-escalation period]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.